|
Ontario-area scientists discuss approaches to development of stem-cell therapies.
Apr 1, 2013
By:
Amy Ritter, PhD
Ontario-area scientists discuss approaches to development of stem-cell therapies.
|
Feb 12, 2013
By:
Amy Ritter, PhD
Eli Lilly and Co. announced that it will discontinue its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy.
|
Feb 5, 2013
By:
Amy Ritter, PhD
FDA has released a list of more than 50 guidance documents planned for 2013.
|
Jan 29, 2013
By:
Amy Ritter, PhD
Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.
|
Jan 22, 2013
By:
Amy Ritter, PhD
According to the Federal Trade Commission, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased between 2011 and 2012.
|
Jan 15, 2013
By:
Amy Ritter, PhD
Lonza will invest CHF 14 million ($15.1 million) to double the existing large-scale manufacturing capacity in Visp, Switzerland.
|
Jan 7, 2013
By:
Amy Ritter, PhD
AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott Pharmaceuticals, was officially launched on Jan. 2, 2013.
|
Dec 31, 2012
By:
Amy Ritter, PhD
Amgen has agreed to pay $762 million to resolve criminal liability and false claims act allegations.
|
Dec 24, 2012
By:
Amy Ritter, PhD
Anthrax antitoxin is the first monoclonal antibody approved under FDA's Animal Efficacy Rule, and the first product from BARDA's Project Bioshield to receive FDA approval.
|
|
